For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > LATEST
LATEST
-
REGULATORY MHLW Outlines Envisaged Cases of Regulatory Submissions without Japanese Data, Covering Rare Disease Drugs
October 24, 2024
-
REGULATORY Contribution to Drug Discovery Up for Discussion in Revising Core Hospital Criteria
October 24, 2024
-
BUSINESS Guardant to Close Japan Lab Due to Sluggish Product Uptake
October 24, 2024
-
REGULATORY Marukawa Touts Importance of Drug Innovation in Lower House Campaign
October 24, 2024
-
BUSINESS NHI-Market Price Gap Expected to Contract in 2024, Will It Enter Lower 5% Territory?
October 24, 2024
-
BUSINESS Otsuka’s IgA Nephropathy Drug Makes Mark in PIII, Eyes Accelerated Path
October 23, 2024
-
BUSINESS Tirzepatide Cuts Body Weight in Japanese Adults with Obesity: PIII
October 23, 2024
-
BUSINESS CEA Is “Wrong Tool” That Doesn’t Fit into Japanese System: J&J Exec
October 23, 2024
-
COLUMN Elevating Leadership: Insights from Japan’s Healthcare Sector
October 23, 2024
-
ACADEMIA Academic Societies Urge COVID-19 Vaccinations, Deny Kostaive “Shedding”
October 22, 2024
-
BUSINESS Takeda to Offer Buyout Package from December as Part of Reorganization
October 22, 2024
-
REGULATORY LDP’s Hashimoto Makes Rare Speech on Drug Prices amid Close Race in Okayama
October 22, 2024
-
BUSINESS Aculys Pharma’s Pitolisant Nets Positive Data in Japan PIII
October 22, 2024
-
BUSINESS Astellas’ Gastric Cancer Med Vyloy Approved in US after Re-Filing
October 22, 2024
-
BUSINESS Pfizer Veteran Pullicino to Lead Novartis Japan
October 22, 2024
-
BUSINESS GSK Japan Targets 8% Average Annual Growth through 2031
October 21, 2024
-
REGULATORY Ex-Health Minister Gets Kostaive Shot, Warns against “Unscientific Concerns”
October 21, 2024
-
BUSINESS Ferring Japan Set for 15% Annual Growth as It Gazes at Gene Therapy Debut
October 21, 2024
-
ORGANIZATION Drug Therapy for Fetal Tachyarrhythmia Gets 1st Health Coverage in Japan
October 21, 2024
-
BUSINESS Real-World Data Confirms Efficacy of Cefiderocol in Drug-Resistant Bacteria
October 18, 2024
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…